Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Research Council grant · Running

GelEV Engineered hyaluronic acid hydrogel for enhanced EV retention and controlled release

Coordinator
University of Galway, Ireland
Runs
1 September 2026 to 29 February 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101334932

What the project is doing

In the project's own words, from its summary on CORDIS.

Extracellular vesicles (EVs) are rapidly emerging as a next-generation therapeutic modality in regenerative medicine and immunomodulation. However, a major translational limitation is their rapid dispersion and clearance following administration. Existing hydrogel delivery systems typically rely on physical encapsulation in gels developed for other biomedical applications, or chemical/ genetic modification of EVs to tether them to hydrogels to achieve retention.

Such approaches lack control over EV release, or can alter EV surface properties, complicate manufacturing, and restrict compatibility to specific EV types. To address this problem, GelEV aims to validate a novel hyaluronic acid (HA)-based hydrogel that enhances EV retention without requiring EV surface modification or encapsulation. This bio- and cyto-compatible platform incorporates hydrogel modifications to prolong local EV availability while preserving native EV structure and function.

By avoiding EV modification steps, the system is designed to be compatible with diverse EV sources and manufacturing pipelines. Thus far, this novel hydrogel demonstrates increased retention of murine MSC-derived EVs. This project will de-risk the technology by verifying hydrogel manufacturability and by validating compatibility with clinically relevant human, lyophilised, and commercially available EV formulations. Functional assays will confirm preservation of bioactivity following sustained release.

The development of an EV-agnostic hydrogel delivery platform will create an enabling technology for the expanding EV therapeutics sector. If successful, the licensable platform will allow EV developers to enhance therapeutic performance by having a controlled EV delivery tool, without altering their EV products, thereby accelerating clinical translation across multiple regenerative and inflammatory indications for patients, positioning it for commercial adoption in research and pharmaceutical contexts.

Topics

Who is involved

OrganisationCityCountryRole
University of GalwayGalwayIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI